Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation

被引:53
作者
Andrews, Peter A. [1 ]
Emery, Vincent C. [2 ]
Newstead, Chas [3 ]
机构
[1] St Helier Hosp, Dept Nephrol, SW Thames Renal & Transplantat Unit, Carshalton SM5 1AA, Surrey, England
[2] UCL Med Sch, Dept Virol, London, England
[3] St James Univ Hosp, Dept Nephrol, Leeds, W Yorkshire, England
关键词
Cytomegalovirus; Guideline; Transplantation; Valganciclovir; REPLACE PREEMPTIVE THERAPY; CYTOMEGALOVIRUS DISEASE; ORAL GANCICLOVIR; RISK-FACTORS; LEFLUNOMIDE FAILURE; PROPHYLAXIS; VALGANCICLOVIR; RECIPIENTS; INFECTION; KIDNEY;
D O I
10.1097/TP.0b013e318235c7fc
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The third edition of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease after Solid Organ Transplantation was published in March 2011. This article summarizes the important changes and advances in management in this rapidly evolving field. The pros and cons of universal, or targeted anti-cytomegalovirus (CMV) prophylaxis, and pre-emptive anti-CMV therapy are discussed, especially with respect to advances in CMV polymerase chain reaction monitoring. The evidence for oral anti-CMV prophylaxis using valganciclovir is presented, together with a summary of the treatment of CMV disease and emerging fields such as CMV vaccination, CMV genotyping, and drug resistance.
引用
收藏
页码:1181 / 1187
页数:7
相关论文
共 63 条
[1]  
[Anonymous], AM J TRANSPLANTAT S5
[2]   Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].
Asberg, A. ;
Humar, A. ;
Rollag, H. ;
Jardine, A. G. ;
Mouas, H. ;
Pescovitz, M. D. ;
Sgarabotto, D. ;
Tuncer, M. ;
Noronha, I. L. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113
[3]   Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients [J].
Asberg, A. ;
Humar, A. ;
Jardine, A. G. ;
Rollag, H. ;
Pescovitz, M. D. ;
Mouas, H. ;
Bignamini, A. ;
Toez, H. ;
Dittmer, I. ;
Montejo, M. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1205-1213
[4]   Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Organ Transplantation: Is Less Really More? [J].
Avery, Robin K. .
CLINICAL INFECTIOUS DISEASES, 2011, 52 (03) :322-324
[5]  
Baillie GM, 2006, AM J HEALTH-SYST PH, V63, pS10, DOI 10.2146/ajhp060378
[6]   Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation [J].
Battiwalla, M. ;
Paplham, P. ;
Almyroudis, N. G. ;
McCarthy, A. ;
Abdelhalim, A. ;
Elefante, A. ;
Smith, P. ;
Becker, J. ;
McCarthy, P. L. ;
Segal, B. H. .
TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (01) :28-32
[7]  
Benedetti E, 1998, CLIN TRANSPLANT, V12, P391
[9]   Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States [J].
Blumberg, Emily A. ;
Hauser, Ingeborg A. ;
Stanisic, Sanja ;
Mueller, Elvira ;
Berenson, Karina ;
Gahlemann, Christoph G. ;
Humar, Atul ;
Jardine, Alan G. .
TRANSPLANTATION, 2010, 90 (12) :1420-1426
[10]   GANCICLOVIR SUSCEPTIBILITIES OF CYTOMEGALOVIRUS (CMV) ISOLATES FROM SOLID-ORGAN TRANSPLANT RECIPIENTS WITH CMV VIREMIA AFTER ANTIVIRAL PROPHYLAXIS [J].
BOIVIN, G ;
ERICE, A ;
CRANE, DD ;
DUNN, DL ;
BALFOUR, HH .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (02) :332-335